Browse the evidence

Obesity is a major contributor to type 2 diabetes, necessitating medication management for both conditions.

Addressing obesity is crucial in managing type 2 diabetes, and medication may be necessary.

Treatment proposals for obesity must be individualized according to phenotyping.

Tailoring obesity treatment plans to individual profiles can enhance effectiveness.

Glucagon-like peptide-1 receptor agonists induce substantial and durable weight loss and improve obesity-related gastrointestinal outcomes.

Practitioners can consider GLP-1 receptor agonists as effective treatments for weight management and gastrointestinal health.

Tirzepatide offers superior glycemic control and weight reduction compared to conventional GLP-1 receptor agonists.

Practitioners may consider Tirzepatide as a more effective option for managing glycemic control and weight in patients with T2DM.

Clinical trials have demonstrated effectiveness in lowering HbA1c and body weight.

Evidence from clinical trials supports the use of Tirzepatide for improving glycemic control and reducing body weight.

Exenatide combined with Metformin significantly reduced insulin resistance (HOMA-IR) by a mean difference of -0.9 (p < 0.001).

Practitioners may consider the combination of Exenatide and Metformin as an effective treatment for improving insulin resistance in women with PCOS.

Exenatide combined with Metformin reduced body mass index (BMI) by a mean difference of -0.4 (p = 0.03).

The combination therapy may assist in weight management for women with PCOS.

Patients experienced an average weight loss of 16.06 ± 7.6 pounds at 12 weeks and 38.82 ± 11.4 pounds at 24 weeks.

Practitioners can expect significant weight loss in patients using compounded GLP-1 ± GIP agonists.

All secondary cardiometabolic outcomes improved significantly throughout the study.

Practitioners can consider compounded GLP-1 ± GIP agonists as effective for improving various cardiometabolic risk factors.

Intensive lifestyle modification and medications that improve insulin resistance are key strategies for preventing type 2 diabetes (T2D).

Practitioners should focus on lifestyle changes and medications to prevent T2D.

35% of protein supplement users take them for muscle mass increase.

Practitioners should emphasize muscle gain in discussions about protein supplementation.

Meal replacements (MRs) lead to a significant reduction in fasting blood sugar (FBS) by 3.10 mg/dL.

Incorporating meal replacements can effectively lower fasting blood sugar levels.

The RESTART trial aims to evaluate whether a complex lifestyle intervention can improve and maintain cardiorespiratory fitness, muscle strength, and body composition among older adults with elevated cardiometabolic risk.

Practitioners can consider implementing complex lifestyle interventions to improve fitness and health in older adults at risk.

Secondary and tertiary outcomes include parameters such as muscle strength, physical activity levels, body composition, and health-related quality of life.

Practitioners should consider these additional outcomes when evaluating the impact of lifestyle interventions.

Weight decreases of 1.0% to 2.9%, 3.0% to 4.9%, and 5.0% or greater are associated with a lower risk of type 2 diabetes by 16%, 25%, and 26%, respectively.

Encouraging weight loss can significantly reduce the risk of developing type 2 diabetes.

Preventing weight gain and reducing weight are important for lowering the risk of type 2 diabetes in individuals with a BMI of 22 or greater.

Healthcare providers should focus on weight management strategies for individuals at risk of type 2 diabetes.

Superset training reduces session duration by approximately 50% compared to traditional resistance training.

Practitioners can recommend superset training as a time-efficient alternative to traditional resistance training.

Chronic data generally indicate that supersets and traditional resistance training lead to similar adaptations for endurance, hypertrophy, power, and strength.

Both training modalities can be used interchangeably for long-term adaptations.

Mean plasma leucine incremental area under curve was greater following rBLG compared with whey.

rBLG may provide a superior source of leucine compared to whey, potentially enhancing muscle protein synthesis.

Training-induced changes in leg lean body mass and leg press 1RM increased after training with no differences between rBLG and whey groups.

Both rBLG and whey can effectively support muscle gains from resistance training.

63.4% of survivors of adolescent and young adult cancer had ≥5% weight reduction after anti-obesity medication initiation.

Practitioners may consider AOMs as a viable option for weight management in this population.

The proportion of survivors with severe obesity decreased from 60% to 35% after anti-obesity medication initiation.

AOMs may effectively reduce severe obesity in this demographic.

Anti-obesity medications are effective for weight reduction in survivors of adolescent and young adult cancer.

AOMs can be considered a treatment option for weight management in AYA cancer survivors.

Semaglutide add-on to metformin significantly decreases the Visceral Adiposity Index (VAI) in type 2 diabetic patients, with the greatest reduction in the obesity group (-0.70).

Incorporating semaglutide with metformin may enhance fat loss in patients with type 2 diabetes, especially those with obesity.